Dr William Hunter has experience in commercialising medical device technologies.
He co-founded Angiotech Pharmaceuticals in 1992 and became chief executive in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ.
Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor including the TAXUS Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter.
He is the president and chief executive of Canary Medical Inc and formerly Correvio Pharma Corp (NASDAQ: CORV), director of Rex Bionics, and an industry expert advisor for BioScience Managers. He was previously a director of Epirus Biopharmaceuticals (NASDAQ: EPRS) and Union Medtech.
